Recombinant Alexa Fluor® 488 Anti-GFAP antibody [EPR1034Y] (ab194324)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alexa Fluor® 488 Rabbit monoclonal [EPR1034Y] to GFAP
- Suitable for: IHC-Fr
- Reacts with: Rat
- Conjugation: Alexa Fluor® 488. Ex: 495nm, Em: 519nm
Related conjugates and formulations
Product nameAlexa Fluor® 488 Anti-GFAP antibody [EPR1034Y]
See all GFAP primary antibodies
DescriptionAlexa Fluor® 488 Rabbit monoclonal [EPR1034Y] to GFAP
ConjugationAlexa Fluor® 488. Ex: 495nm, Em: 519nm
Tested applicationsSuitable for: IHC-Frmore details
Species reactivityReacts with: Rat
Predicted to work with: Mouse, Human
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
- IHC-Fr: Rat brain (Hypothalamus).
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or firstname.lastname@example.org.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Alexa Fluor® 647 Anti-GFAP antibody [EPR1034Y] (ab194325)
- Alexa Fluor® 594 Anti-GFAP antibody [EPR1034Y] (ab201732)
- Alexa Fluor® 555 Anti-GFAP antibody [EPR1034Y] (ab201735)
- Alexa Fluor® 568 Anti-GFAP antibody [EPR1034Y] (ab201736)
- Alexa Fluor® 405 Anti-GFAP antibody [EPR1034Y] (ab206586)
- Anti-GFAP antibody [EPR1034Y] - BSA and Azide free (ab218309)
- Anti-GFAP antibody [EPR1034Y] (ab68428)
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab194324 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
Tissue specificityExpressed in cells lacking fibronectin.
Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
Sequence similaritiesBelongs to the intermediate filament family.
modificationsPhosphorylated by PKN1.
Cellular localizationCytoplasm. Associated with intermediate filaments.
- Information by UniProt
- Entrez Gene: 2670 Human
- Entrez Gene: 14580 Mouse
- Entrez Gene: 24387 Rat
- Omim: 137780 Human
- SwissProt: P14136 Human
- SwissProt: P03995 Mouse
- SwissProt: P47819 Rat
- Unigene: 514227 Human
- wu:fb34h11 antibody
- ALXDRD antibody
- cb345 antibody
IHC-Fr image of GFAP staining in a section of frozen rat brain (hypothalamus). The section was air dried on the bench for 30 minutes and blocked for 2 hours in 1XPBS/0.1% Tween 20/1% BSA/0.3M Glycine buffer. The sample was then incubated overnight at +4°C with ab194324 at 1/50 dilution (shown in green). DAPI-containing mounting media was added to the sample (shown in blue). The inset negative control image is taken from an identical assay without primary antibody.
Datasheets and documents
ab194324 has been referenced in 2 publications.
- Kamynina A et al. Activation of RAGE leads to the release of glutamate from astrocytes and stimulates calcium signal in neurons. J Cell Physiol 236:6496-6506 (2021). PubMed: 33570767
- Turovsky EA et al. Mechanosensory Signaling in Astrocytes. J Neurosci 40:9364-9371 (2020). PubMed: 33122390